Onabotulinum toxin a treatment for posttraumatic trigeminal neuropathic pain: case series and literature review

Research output: Contribution to journalArticlepeer-review

Abstract

This case series aimed to assess the treatment outcomes of onabotulinum toxin A (BTX-A) in patients with refractory posttraumatic trigeminal neuropathic pain (PTNP) and to conduct a narrative review of the evidence for BTX-A in PTNP. Thirteen patients were treated with BTX-A infiltrations. Patient demographic and pain characteristics, BTX-A administration, and treatment outcomes were retrospectively analyzed. Papers retrieved after a literature search of articles on PTNP treatment using BTX-A were reviewed. Six patients reported an improvement in pain 3 months after the initial BTX-A injection, with 4 patients reporting a 50% reduction. Two patients achieved an 80% reduction in pain score over 3 years of BTX-A therapy. Three patients reported temporary ipsilateral facial muscle weakness. The literature review revealed five case reports on the use of BTX-A in PTNP patients that reported similar effectiveness to the present cohort study. BTX-A may be a potential treatment modality for refractory PTNP, thus reducing the need for polypharmacy. Multiple intraoral BTX-A injections administered over the painful sites are well tolerated, safe and easily practiced. High-quality studies are required to evaluate the long-term therapeutic efficacy and side effects of BTX-A therapy.

Original languageEnglish
Pages (from-to)93-105
JournalJournal of Oral and Facial Pain and Headache
Volume38
Issue number1
Early online date12 Mar 2024
DOIs
Publication statusE-pub ahead of print - 12 Mar 2024

Fingerprint

Dive into the research topics of 'Onabotulinum toxin a treatment for posttraumatic trigeminal neuropathic pain: case series and literature review'. Together they form a unique fingerprint.

Cite this